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large budgets by various government 
agencies that have permitted intense 
collaboration among scientists as well 
as engagement of industry for the 
development of supporting technolo-
gies. The funding made available for 
these projects contrasts sharply with 
the relatively limited budgets that have 
been available for gene therapy research. 
Typically, most gene therapy researchers 
work as small teams on a specific disease 
with a relatively small budget. Moreover, 
the funding for gene therapy research 
tends to be piecemeal, with part coming 
from private foundations supported by 
patients, parents, and friends. Although 
these small groups can provide proof 
of concept for a gene therapy approach 
in cell and animal models, they gener-
ally lack the expertise and funding to 
efficiently translate their strategies to a 
clinical trial.
The fragmentation of gene therapy 
research efforts and the limited fund-
ing thus present significant hurdles 
for clinical translation. The establish-
ment of an international gene therapy 
consortium would allow these small 
groups to tap into broader expertise 
and infrastructure, increasing the 
likelihood of a potentially beneficial 
treatment moving to clinical trials. 
There are already smaller consortia that 
can serve as examples. Indeed, Euro-
pean Union–sponsored collaborative 
networks in Europe have demonstrated 
the advantages of consortia-fostered 
collaboration among basic scientists, 
clinical investigators, industry, patient 
organizations and regulatory authori-
ties. This format of collaboration and 
interactive multidisciplinary networks 
is ideally suited to address the various 
challenges of this multifaceted field. 
Consequently, such a concerted effort 
is much more cost-effective. One such 
group, the Transatlantic Gene Therapy 
Consortium, has successfully devel-
oped gene therapy strategies and trials 
predominantly for rare hematologic and 
immunologic diseases. In the EU Sev-
enth Framework Programme, two pan-
European translational projects have 
been funded, one focusing on neuro-
logical and neurodegenerative diseases 
(NEUROMICS), the other on rare 
diseases of the kidney (EuRenOmics). 
In the United States, the Rare Diseases 
Clinical Research Network was funded 
by the National Institutes of Health and 
the Office for Rare Diseases Research in 
order to facilitate collaboration among 
experts in many types of rare diseases. 
The FORGE Canada project, a national 
consortium of clinicians and scientists, 
is using next-generation sequencing 
technology to identify genes responsible 
for 200 rare pediatric-onset disorders 
and investigate their molecular eti-
ology. The International Rare Dis-
eases Research Consortium (IRDiRC), 
launched in April 2011, aims to foster 
international collaboration, maximizing 
resources and coordinating efforts in 
rare-diseases research. Worldwide shar-
ing of information, data, and samples 
is currently hampered by the absence 
of an exhaustive rare-disease classi-
fication, standard terms of reference, 
common ontologies, and harmonized 
regulatory requirements. The IRDiRC 
has two main objectives to achieve by 
the year 2020: to deliver 200 new thera-
pies for rare diseases and the means to 
diagnose most rare diseases. The group 
will next develop the scientific and 
policy framework to guide research ac-
tivities and foster collaboration among 
the stakeholders to systematically 
explore the opportunities to acceler-
ate the development of diagnostics and 
therapies for rare diseases. However, it 
should be emphasized that currently the 
majority of the 200 therapies sought by 
this consortium are based on the use 
of small molecules rather than on gene 
and/or cell therapy.
We believe that there is a need for 
a larger gene therapy consortium, with 
a larger budget, to focus on developing 
definitive gene and cell therapy treat-
ments for most monogenic hereditary 
diseases over the next 20 years. This 
consortium will permit the develop-
ment of focused areas of expertise. A 
major impediment to the commercial-
ization of gene therapy for rare diseases 
lies in the lack of a sound business 
model for companies owing to the small 
number of patients, the fact that a single 
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To the editor:
Over the past decade, gene therapy has 
been successfully used to treat several 
monogenic disorders, and it shows 
promise for treating diseases of more 
complex etiology. In addition, the 
recent development of induced pluripo-
tent stem cells now opens the possibility 
of transplanting genetically corrected 
autologous cells.1,2 Very recently, the 
European Medicines Agency approved 
the first gene therapy treatment in the 
Western world.3 The substantial prog-
ress over the preceding decades argu-
ably portends the development of gene 
therapies for most monogenic diseases. 
Given this remarkable opportunity, we 
are proposing the creation of an Inter-
national Gene Therapy Consortium for 
Monogenic Diseases. This consortium 
would facilitate coordination of the 
production and availability of a variety 
of vectors, oligonucleotides, and recom-
binant proteins—including zinc-finger 
nucleases and Tal effector nucleases—as 
well as support the development of 
suitable animal models, preclinical 
studies, and clinical trials. Financial 
resources should be developed so as to 
attract collaborations from the private 
sector to boost the development of a 
gene therapy industry, similar to the 
way the Apollo project to explore the 
moon stimulated growth of the space 
and computer industries in the 1960s. 
In this century, a similar concerted ef-
fort will be required to develop effective 
treatments and even cures of diseases 
here on Earth!
A model for such a consortium 
can be found in the field of genomics. 
Advances in genomics have been rapid, 
owing in large part to the formation 
of international consortia such as the 
Human Genome and the ENCODE 
(Encyclopedia of DNA Elements) proj-
ects. These consortia have been awarded 
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treatment can cure a patient for life, and 
the requirements for long-term evalu-
ation by federal agencies. As recently 
suggested, public funds could be used 
to pay for centralized manufacturing 
facilities and to subsidize enterprises 
with the necessary expertise, as has 
been done for vaccines.4 A worldwide 
consortium would also facilitate the as-
sembly of larger cohorts of patients with 
specific rare diseases, which are present 
in very small numbers in individual 
countries; this would allow for more 
robust clinical trial designs. Finally, a 
gene therapy consortium could facilitate 
long-term evaluation of integration sites 
and adverse events so as to better track 
the safety of new therapies. The cre-
ation of an International Gene Therapy 
Consortium for Monogenic Diseases 
would thus be, for these diseases, the 
first concrete step toward the personal-
ized medicine that genomic research 
makes possible. It should be emphasized 
that some of these diseases (e.g., sickle 
cell disease and b-thalassemia) affect 
millions of peoples.
Like mankind’s quest to travel to 
the moon in the 1960s, this proposal 
represents a grand challenge, but we 
have a societal obligation to the rare-
disease community to collaborate and 
build the infrastructure to meet it. With 
an international consortium in place, 
it is more likely that therapies will be 
established that help patients not only 
in the developed world but also in less 
developed parts of our planet. Impor-
tantly, current scientific developments 
make this a timely challenge, and, in 
the long term, gene therapies for these 
diseases should become cost-effective. 
Just as we witnessed with the Human 
Genome Project, the technologies to 
correct the human genome will progress 
over the years with the appropriate in-
centives, generating a boost for the new 
knowledge-based economy. The time to 
take this step is now.
The scientists and directors of 
foundations or patient associations 
that would like to support the creation 
of such a consortium are invited to e-
mail Jacques P. Tremblay at Jacques-P.
Tremblay@crchul.ulaval.ca.
doi:10.1038/mt.2013.4
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